Verdence Capital Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $668K | Sell |
5,290
-960
| -15% | -$126K | 0.04% | 376 |
|
|
2026
Q1 | $871K | Sell |
6,250
-4,905
| -44% | -$687K | 0.05% | 314 |
|
|
2025
Q4 | $1.37M | Sell |
11,155
-1,806
| -14% | -$219K | 0.08% | 232 |
|
|
2025
Q3 | $1.56M | Sell |
12,961
-2,060
| -14% | -$234K | 0.09% | 217 |
|
|
2025
Q2 | $1.67M | Sell |
15,021
-5,191
| -26% | -$552K | 0.11% | 184 |
|
|
2025
Q1 | $2.26M | Sell |
20,212
-4,514
| -18% | -$466K | 0.17% | 128 |
|
|
2024
Q4 | $2.28M | Sell |
24,726
-1,973
| -7% | -$178K | 0.18% | 133 |
|
|
2024
Q3 | $2.24M | Buy |
26,699
+3,261
| +14% | +$249K | 0.18% | 148 |
|
|
2024
Q2 | $1.61M | Buy |
23,438
+2,929
| +14% | +$195K | 0.14% | 177 |
|
|
2024
Q1 | $1.5M | Buy |
20,509
+7,249
| +55% | +$557K | 0.14% | 185 |
|
|
2023
Q4 | $1.07M | Sell |
13,260
-166
| -1% | -$12.9K | 0.1% | 208 |
|
|
2023
Q3 | $1.01M | Buy |
13,426
+2,069
| +18% | +$159K | 0.11% | 208 |
|
|
2023
Q2 | $875K | Sell |
11,357
-4,227
| -27% | -$337K | 0.1% | 216 |
|
|
2023
Q1 | $1.29M | Sell |
15,584
-9,346
| -37% | -$774K | 0.16% | 158 |
|
|
2022
Q4 | $2.14M | Sell |
24,930
-3,732
| -13% | -$296K | 0.26% | 93 |
|
|
2022
Q3 | $1.77M | Buy |
28,662
+1,505
| +6% | +$94.9K | 0.24% | 109 |
|
|
2022
Q2 | $1.68M | Buy |
27,157
+525
| +2% | +$32.5K | 0.22% | 118 |
|
|
2022
Q1 | $1.58M | Buy |
26,632
+5,354
| +25% | +$342K | 0.18% | 130 |
|
|
2021
Q4 | $1.54M | Buy |
21,278
+700
| +3% | +$48.2K | 0.18% | 126 |
|
|
2021
Q3 | $1.44M | Buy |
20,578
+493
| +2% | +$34.6K | 0.19% | 128 |
|
|
2021
Q2 | $1.38M | Buy |
20,085
+2,406
| +14% | +$161K | 0.19% | 122 |
|
|
2021
Q1 | $1.14M | Buy |
17,679
+11,152
| +171% | +$719K | 0.19% | 131 |
|
|
2020
Q4 | $380K | Sell |
6,527
-5,805
| -47% | -$350K | 0.07% | 248 |
|
|
2020
Q3 | $779K | Buy |
12,332
+6,758
| +121% | +$469K | 0.18% | 136 |
|
|
2020
Q2 | $429K | Sell |
5,574
-9,180
| -62% | -$704K | 0.11% | 201 |
|
|
2020
Q1 | $1.1M | Buy |
14,754
+1,473
| +11% | +$102K | 0.33% | 84 |
|
|
2019
Q4 | $863K | Sell |
13,281
-695
| -5% | -$45.3K | 0.21% | 116 |
|
|
2019
Q3 | $886K | Buy |
+13,976
| New | +$914K | 0.25% | 118 |
|
|
2018
Q2 | – | Sell |
-4,674
| Closed | -$352K | – | 300 |
|
|
2018
Q1 | $352K | Sell |
4,674
-3,451
| -42% | -$274K | 0.08% | 200 |
|
|
2017
Q4 | $582K | Buy |
+8,125
| New | +$617K | 0.14% | 135 |
|
Other funds holding GILD
Verdence Capital Advisors's GILD Position: Q2 2026 in Review
Verdence Capital Advisors reduced its Gilead Sciences (GILD) stake by 15% in Q2 2026, selling an estimated $126K and leaving 5,290 shares worth $668K. The position accounts for 0.04% of the portfolio, ranked #376.
Verdence Capital Advisors first reported a position in GILD in Q4 2017 and has held it in 30 quarters since. The position peaked at $2.28M in Q4 2024. 2,279 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Verdence Capital Advisors held 5,290 shares of Gilead Sciences worth $668K as of Q2 2026.
- Verdence Capital Advisors sold 960 Gilead Sciences shares in Q2 2026, an estimated $126K.
- Gilead Sciences made up 0.04% of Verdence Capital Advisors's portfolio in Q2 2026, its #376 holding.
- Verdence Capital Advisors first reported a position in Gilead Sciences in Q4 2017 and has held it in 30 quarters since.
- Verdence Capital Advisors's Gilead Sciences position peaked at $2.28M in Q4 2024.
- 2,279 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Verdence Capital Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.